Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
BIOVF's 9-Day RSI is ranked worse than 67.91% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 50.66
vs BIOVF: 99.96
Swedish Orphan Biovitrum AB (OTCPK:BIOVF) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Swedish Orphan Biovitrum AB 9-Day RSI Related Terms
BIOVF vs ZTS, UTHR: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's 9-Day RSI falls into.
Swedish Orphan Biovitrum AB (OTCPK:BIOVF) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (BIOVF) has a 9-Day RSI of 99.96 as of Jul. 13, 2026. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #711 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 67.9%.
Is Swedish Orphan Biovitrum AB's 9-Day RSI too high?
Swedish Orphan Biovitrum AB's current 9-Day RSI is 99.96. The Drug Manufacturers industry median 9-Day RSI is 50.66. Swedish Orphan Biovitrum AB's value of 99.96 is 97.3% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #711 out of 1047 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's 9-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #711 out of 1047 companies for 9-Day RSI. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median 9-Day RSI is 50.66. Swedish Orphan Biovitrum AB's value of 99.96 is 97.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 50.66, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current 9-Day RSI of 99.96 is 97.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 50.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current 9-Day RSI is 99.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (BIOVF) is currently considered Significantly Overvalued. The stock's GF Value™ is $34.92, compared to a current price of $49.03 — trading 40.4% above its estimated fair value. The current 9-Day RSI is 99.96 and 97.3% above the Drug Manufacturers industry median of 50.66. Swedish Orphan Biovitrum AB's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (BIOVF), the current 9-Day RSI is 99.96 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (BIOVF) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $49.03 is trading 40.4% above its estimated GF Value™ of $34.92.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for BIOVF:
9-Day RSI: 99.96
GF Value™: $34.92 vs. price of $49.03 (40.4% above fair value)
Industry Position: 97.3% above the Drug Manufacturers median (#711 of 1047)
No single metric tells the full story. See the BIOVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
83GF Score
Get the complete analysis for BIOVF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOVF has been successfully added to your 
